Entering text into the input field will update the search result below

MediciNova rallies on positive ibudilast data in alcohol use disorder

Aug. 06, 2020 7:14 AM ETMediciNova, Inc. (MNOV) StockMNOVBy: Douglas W. House, SA News Editor
  • MediciNova (NASDAQ:MNOV) announces positive results from a Phase 2 clinical trial evaluating MN-166 (ibudilast) for the treatment of alcohol use disorder (AUD). The results were presented virtually at the American Psychological Association Annual Meeting.
  • Ibudilast significantly reduced the number of heavy drinking days compared to placebo (p=0.03).
  • There was a significant effect of ibudilast on alcoholic beverage images (ALC) versus non-alcoholic beverage images (BEV) percent signal change in the bilateral ventral striatum (VS) evaluated by fMRI (p=0.02). 
  • Predicting Drinking by Medication: Significant interaction between ibudilast and activation in the VS on subsequent drinking (p=0.02). Patients treated with ibudilast and had attenuated VS activation drank the least in the week after the scan.
  • Ibudilast significantly reduced binge drinking after 14 days of treatment.
  • Shares up 10% premarket on average volume.

Recommended For You

More Trending News

About MNOV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MNOV--
MediciNova, Inc.